Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 4, 2024American Journal of Hematology

Anti‐CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

ATAung M. TunUniversity of KansasRPRomil PatelThe University of Texas MD Anderson Cancer CenterFSFrédérique St‐PierreSoutheastern Community College - Iowa

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tun et al. (2024) studied this question.

synapsesocial.com/papers/68e66368b6db6435875f0852https://doi.org/10.1002/ajh.27381
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017 · 6,114 citations
  2. 2Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma2023 · 103 citations
  3. 3Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study2022 · 15 citations
  4. 4Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience2021 · 35 citations